EUVIMEDEUVIMED entdecken
Kohortenstudie

A Real‐World Retrospective Cohort Study on the Use of Dupilumab for Severe Atopic Dermatitis in Patients Aged 6 Months to 16 Years

Laura Wheller, Samuel Fordham iD, Michael Cao, Tania Zappala, Genevieve Casey, Heba Jibreal iD, Nerilee Wall, Amanda Dore

Australasian Journal of Dermatology · 2026

DOI: 10.1111/ajd.70031 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Australasian Journal of Dermatology, 2026. Verfasst von Laura Wheller und 7 weiteren Autor:innen. Beteiligte Einrichtung: Queensland Children's Hospital, South Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Queensland Cyber Infrastructure Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dupilumab is a known treatment for atopic dermatitis (AD). However, there is limited data on the effectiveness and safety of its use within the paediatric population.

Objective

The objective of this study was to determine the effectiveness and safety of dupilumab in children under 16 years with moderate‐to‐severe AD.

Methods

162 children aged 6 months to 16 years with moderate‐to‐severe AD were treated with dupilumab. Dupilumab was accessed through the Pharmaceutical Benefits Scheme (PBS) for those aged 12 and above. Those aged under 12 years accessed dupilumab with applications to the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) as a category B application. Such applications were then processed through the hospital pharmacy as an individual patient approval (IPA). Treatment was surveyed over a 3‐year period from 2020 to 2023. Treatment effect was determined by overall clinical disease severity with the Eczema Area and Severity Index (EASI) score. Scores were repeated at serial appointments following dupilumab doses. All data were collected from a single Australian tertiary referral paediatric hospital and tabulated in an Excel spreadsheet.

Results

A significant improvement was observed for almost all patients, with 87% achieving at least a 75% reduction in EASI scores. Adverse effects occurred in 30% of patients, although these were mostly minor and transient. Only four patients (2.4%) ceased dupilumab due to adverse effects or failure to respond.

Limitations

Retrospective cohort design.

Conclusion

Our findings demonstrate dupilumab's long‐term effectiveness and safety in treating atopic dermatitis in the paediatric population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedDermatologic AgentsHumansChildRetrospective StudiesAdolescentMaleFemaleInfantChild, PreschoolSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

atopybiologicchildrendermatitisdupilumabeczemapaediatric

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedDermatologic Agents

Autor:innen und Institutionen

  • Queensland Children's Hospital, South Brisbane, Queensland, Australia.
  • Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.

ORCID-Profile: Samuel Fordham, Heba Jibreal

Förderung

  • Queensland Cyber Infrastructure Foundation

Zitieren

APA

Wheller, L., Fordham, S., Cao, M., Zappala, T., Casey, G., Jibreal, H., Wall, N., & Dore, A. (2026). A Real‐World Retrospective Cohort Study on the Use of Dupilumab for Severe Atopic Dermatitis in Patients Aged 6 Months to 16 Years. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.70031

Vancouver

Wheller L, Fordham S, Cao M, Zappala T, Casey G, Jibreal H, et al. A Real‐World Retrospective Cohort Study on the Use of Dupilumab for Severe Atopic Dermatitis in Patients Aged 6 Months to 16 Years. Australasian Journal of Dermatology. 2026. doi:10.1111/ajd.70031

BibTeX
@article{Wheller2026,
  author = {Wheller, Laura and Fordham, Samuel and Cao, Michael and Zappala, Tania and Casey, Genevieve and Jibreal, Heba and Wall, Nerilee and Dore, Amanda},
  title = {A Real‐World Retrospective Cohort Study on the Use of Dupilumab for Severe Atopic Dermatitis in Patients Aged 6 Months to 16 Years},
  journal = {Australasian Journal of Dermatology},
  year = {2026},
  doi = {10.1111/ajd.70031}
}
Kostenlos starten →